Pinsent Masons collaborates with LifeArc on expert paper to support drug repurposing

15 Jun 2021 | 01:32 pm | 2 min. read

Multinational law firm Pinsent Masons has collaborated with medical research charity LifeArc, on a new report offering expert advice, insights and practical tips to charities, researchers and funders hoping to repurpose drugs for other – often rare and fatal – conditions.

The pandemic has placed drug repurposing high on the agenda, with medications such as the steroid dexamethasone and rheumatoid arthritis treatment tocilizumab being used to treat patients severely ill with Covid-19.

Charities and patient groups seeking treatments for rare diseases are often particularly interested in the potential of new uses for existing drugs because they offer the possibility of lower overall costs and shorter timeframes to get treatments to patients and licensed medications already have known safety profiles.

The guide, Repurposing medicines: the opportunity and the challenges was launched today at the Findacure's virtual Drug Repurposing for Rare Diseases Conference 2021 and has a range of practical tips and advice for overcoming potential barriers including:

  • Seeking scientific advice from the regulator

  • Developing an intellectual property strategy

  • Collaborating with industry on drug repurposing opportunities

  • Taking steps to ensure medicines are made available to patients

Commenting on the report LifeArc CEO Dr Melanie Lee, CBE said:

The pandemic has shown what is possible in the field of drug repurposing. However, we know that not–for–profits and researchers can be confused by the complex commercial and regulatory challenges that repurposing presents. We want to improve awareness of those challenges so that applications for repurposing proceed smoothly – making it more likely that life-changing medicines will reach patients in the clinic. That translational science is LifeArc’s area of expertise – ensuring that successful lab research results in new treatments or therapies for patients as quickly as possible.”

Nicole Jadeja, life sciences partner at Pinsent Masons, said:

“We are delighted to have partnered with LifeArc on this important project and hope that this will provide practical advice to help convert more repurposing projects into new treatments for patients. One thing that really stands out is how important collaboration is in delivering on the promise of repurposing and drawing upon the experiences of the wide range of stakeholders in the guide."

The guide provides clear examples of the benefits of finding new uses for existing medicines including the repurposing of the breast cancer drug tamoxifen for treating X-linked myotubular myopathy (a rare neuromuscular disorder that mainly affects boys), using a vertigo drug as a treatment for certain rare and devastating neurodegenerative diseases and the successful repurposing of a drug called rapamycin which has transformed the lives of women with lymphangioleiomyomastosis (LAM).

Findacure CEO Dr Rick Thompson said:

"In the world of rare diseases, millions of patients live with no treatment. Drug repurposing offers a quick, cheap, accessible and patient-friendly route to develop new treatments for rare diseases, and in recent years the field has grown steadily. However, we must address roadblocks – including a lack of financial incentive for industry and a lack of regulatory knowledge in academia. We can't wait to get working with LifeArc to deliver change. COVID-19 has shown what can be achieved in repurposing with the right funding and government incentives. Now, those benefits must reach the world's 350 million rare disease patients."

Latest press releases

Show me all press releases

Pinsent Masons MPillay advises SUSI Partners on investment in Alba Renewables

Law firm Pinsent Masons MPillay has advised Swiss-based infrastructure investment manager SUSI Partners on its investment in Alba Renewables to build a renewable energy infrastructure business focused on The Philippines.

Pinsent Masons advises La Bottega on Australian acquisition

Multinational law firm Pinsent Masons has advised Italian producer of hotel essentials La Bottega on its acquisition of a majority stake in Australian company Vanity Group.

Pinsent Masons promotes 22 to its partnership

Multinational law firm Pinsent Masons has boosted its global professional services capabilities with the promotion of 22 new partners.

People who viewed this press release also viewed

Show me all press releases

Pinsent Masons advises Sandoz on acquisition of remaining shares in Rowex Joint Venture

Multinational law firm Pinsent Masons has advised Sandoz on the acquisition of the remaining shares in Rowex Limited, a joint venture in Ireland between Sandoz and Rowa Pharmaceuticals.

Pinsent Masons appoints two partners and team of lawyers to launch TMT practice in Australia

Multinational law firm Pinsent Masons has appointed James Arnott and Veronica Scott and a team of lawyers to launch the firm’s Technology, Media and Telecommunications (TMT) practice in Australia.

Pinsent Masons advises supervisory board of Telefónica Deutschland Holding in connection with the public tender offer of Telefónica

Multinational law firm Pinsent Masons has advised the supervisory board of Telefónica Deutschland Holding AG in connection with the public tender offer of its Spanish majority shareholder Telefónica, S.A.

For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on

+44 (0)20 7418 8199 or 

Location contacts

We are processing your request. \n Thank you for your patience. An error occurred. This could be due to inactivity on the page - please try again.